Ipamorelin

Ipamorelin is a synthetic pentapeptide studied for selective stimulation of growth-hormone release through the ghrelin receptor.

Agonizes the growth-hormone secretagogue receptor GHS-R1a, promoting pulsatile growth-hormone release and downstream IGF-1 signaling.

Limited human investigation with additional animal and mechanistic research.

Level III, Limited human evidence

Clinical evidence is limited, and outcomes depend on endocrine context, assay timing, formulation, and exact product identity.

Potential concerns include glucose dysregulation, edema, headache, endocrine effects, and immunogenicity or impurity risks.

No FDA-approved drug product; FDA has previously raised compounding eligibility and safety concerns for ipamorelin.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• Ipamorelin, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.